Cardiogen: A Cardiac-Tropic Tetrapeptide Bioregulator

Research summary. Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg) belonging to the family of short peptide bioregulators developed by the Khavinson laboratory. As with other members of this family, it is reported to act in a tissue-selective manner — in this case on cardiac tissue, with effects on cardiomyocyte and fibroblast biology described in the rodent literature. Cardiogen is sometimes referred to in the source literature by alternative codes; the canonical four-residue sequence is the most consistent identifier.

Molecular profile

• Sequence: Ala-Glu-Asp-Arg (AEDR)
• Molecular formula: C₁₈H₃₁N₇O₉
• Molecular weight: ~489.5 g/mol
• PubChem CID: 11583989
• Class: Short peptide bioregulator (Khavinson peptides) — cardiac tropism

The molecule is a member of the broader bioregulator concept — a research programme proposing that tetrapeptides assembled from particular amino-acid combinations can interact with chromatin to selectively activate or attenuate tissue-specific gene-expression programmes. Each member of the family is associated with a target organ system; Cardiogen is associated with the heart and vasculature.

Mechanism of action

The Khavinson group has proposed a unifying model in which short bioregulator peptides cross the cell and nuclear membranes, interact directly with the DNA double helix or with chromatin-associated proteins, and modulate transcription of tissue-specific gene sets. For Cardiogen, the relevant proposed targets include:

• Cardiomyocyte proliferation and survival genes
• Fibroblast activation and ECM remodelling pathways
• p53-dependent apoptotic signalling, with reported tissue-context-dependent effects

A consistent observation across the bioregulator literature is that effects are reportedly more pronounced in older or stressed tissue than in young, healthy tissue — consistent with the model's hypothesis that the peptides preferentially restore expression of genes silenced by age-associated chromatin remodelling.

Preclinical research highlights

Cardiac tissue. Rat studies in the Khavinson programme have reported that Cardiogen administration is associated with increased cardiomyocyte proliferation markers and reduced fibroblast overactivity in models of cardiac stress, with a net effect of attenuating maladaptive remodelling. Down-regulation of p53-driven apoptosis in cardiomyocytes has been described as one component of this profile.

Tumour models. A counterpoint observation is that in tumour-cell systems (notably murine M-1 sarcoma models), Cardiogen has been reported to enhance rather than suppress apoptosis — a reversal interpreted as context-dependent regulation of p53. This bidirectional behaviour, while sometimes raised as an argument for tissue-selectivity, is also a reminder that the molecular mechanism is not yet fully characterised.

Prostate stromal models. Independent investigations have reported that Cardiogen normalises age-associated alterations in fibroblast paracrine signalling in prostate stromal cell preparations, an observation framed within the broader bioregulator hypothesis of tissue rejuvenation.

Vascular and blood-pressure models. Some preclinical work has reported modulation of vascular tone and blood pressure in rodent models, though the body of evidence for vascular activity is more limited than for direct cardiac effects.

Limitations of the current evidence base

As with other Khavinson bioregulators, several caveats apply to Cardiogen specifically:

• The supporting publications originate predominantly from a single research programme and its collaborators, and are concentrated in Russian-language gerontology journals with smaller English-language exposure.
• The proposed mechanism — direct DNA or chromatin engagement by an unmodified tetrapeptide — remains controversial in the broader peptide pharmacology literature, and has not been independently confirmed at the molecular-structural level.
• No registered Phase 2 or Phase 3 clinical trials of Cardiogen are listed in the major Western trial registries at the time of writing.
• Reported tissue-selectivity has not been rigorously characterised at the level of receptor binding or distribution kinetics.

Current research status

Cardiogen remains an investigational research peptide within the bioregulator research programme. Its principal roles in current research are:

• A reference compound in the broader Khavinson bioregulator family, often studied alongside Bronchogen, Cortagen, Pinealon, Vesugen, and others
• A research tool for examining tissue-selective effects of short peptides in cardiac and fibroblast cell preparations
• A geroprotective candidate within the bioregulator framework

It is not approved as a therapeutic by any major regulatory authority.

Key takeaways for researchers

• Cardiogen is a tetrapeptide (Ala-Glu-Asp-Arg) member of the Khavinson short-peptide bioregulator family, with reported tropism for cardiac tissue.
• Its proposed mechanism involves direct DNA or chromatin interaction and tissue-selective transcriptional modulation.
• Preclinical effects span cardiomyocyte proliferation, fibroblast modulation, and p53-related apoptotic signalling — with reportedly bidirectional context-dependent activity.
• The supporting literature is concentrated in a single research programme. Independent validation is limited.
• Cardiogen is not an approved therapeutic.

References

1. Khavinson VK, Linkova NS, Tarnovskaya SI, et al. Short peptides stimulate cell regeneration: from theory to clinical practice. Bulletin of Experimental Biology and Medicine. 2014;156(3):283–289.
2. Khavinson VK, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Karger. 2005. (Monograph summarising bioregulator family pharmacology.)

---

This article is provided for educational and research purposes only. Cardiogen is a research peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.